Skip to content
Search for:
Twitter
YouTube
LinkedIn
Email
ABOUT
Company
Leadership
Laboratory
Careers
Notice to Recruiters
PRODUCTS
IMMUNO-/ PRECISION ONCOLOGY
ImmunoID NeXT Platform
NeXT Liquid Biopsy
ONCOLOGY CLINICAL DIAGNOSTICS
NeXT Dx Test
PHARMA RESEARCH SOLUTIONS
Exome Sequencing
Transcriptome Sequencing
Whole Genome Sequencing
Targeted Cancer Panels
miRNA Sequencing
APPLICATIONS
Biomarker Discovery
Personalized Therapeutics
TECHNOLOGY
Our Processes
Unlock the power of DNA
Optimizing RNA
NeoantigenID
MHC binding prediction
ImmunogenomicsID
Reliable delivery
RESOURCES
What’s New
Conferences
Library
Blog
Contact
INVESTORS
Overview
Press Releases
Events
SEC Filings
Stock Information
Corporate Governance
Analyst Coverage
Investor FAQs
Contact IR
Email Alerts
Request Info
Blog
marcom
2020-05-16T05:58:35-08:00
Blog
Next >
Synthetic Lethality: Therapeutically exploiting this mechanism and discovering biomarkers of response
August 12th, 2020
by: Kadar Hastak
READ MORE
The Battle Continues: Facing the obstacle of tumor resistance to immunotherapy treatment
December 10th, 2018
by: Erin Newburn, MS, PhD
READ MORE
Five unanswered questions regarding personalized neoantigen cancer vaccines
July 23rd, 2018
by: Erin Newburn, MS, PhD
READ MORE
Comparing and contrasting CTLA-4 and PD-L1/PD-1: A tale of two immune checkpoint inhibitors
May 16th, 2018
by: Erin Newburn, MS, PhD
READ MORE
Understanding the role of HLA in Cancer Immunotherapy
March 5th, 2018
by: Erin Newburn, MS, PhD
READ MORE
Next >
Go to Top
